Director Vern Lee Schramm will not stand for re-election at First Wave BioPharma's Dec 17 annual meeting

GridAI Technologies Corp.

Director Vern Lee Schramm, Ph.D. notified board he will not stand for re-election at annual meeting scheduled for December 17, 2021.
His term as director expires at the close of the annual meeting.
Schramm's decision was not due to any disagreement with the company on operations, policies, or practices.
No replacement has been announced; the board will be reduced by one after the meeting.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Vern Lee Schramm

Director

GRDX · GridAI Technologies Corp.

Effective: 2021-12-17
Filed: November 9, 2021, 6:59 PM ET

On November 4, 2021, Vern Lee Schramm, Ph.D., provided notice to the Board of Directors of First Wave BioPharma, Inc. (the “Company”), that he would not stand for re-election as director at the Company’s upcoming annual meeting of stockholders (the “Annual Meeting”), currently scheduled for December 17, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Vern Lee Schramm departed as Director at GridAI Technologies Corp..

Action: will not stand for re-election
Role: Director

Exact text from the filing

On November 4, 2021, Vern Lee Schramm, Ph.D., provided notice to the Board of Directors of First Wave BioPharma, Inc. (the “Company”), that he would not stand for re-election as director at the Company’s upcoming annual meeting of stockholders (the “Annual Meeting”), currently scheduled for December 17, 2021.

View on SEC.gov

GridAI Technologies Corp. filing history →

Source: SEC EDGAR

accession 0001851734-21-000052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.